Welcome! Translational Therapeutics, Inc. is a pharmaceutical company based in the Boston metropolitan area.
We are focused on developing an important new set of targeted, small molecule cancer therapeutics and diagnostic tools applicable to the safe and effective treatment of human cancers.
Our lead small molecule therapeutic agent targets a central 'gating' function active in the cancerous process and known to be elevated in over twenty-five percent of human cancers .. In short, when the gate is open > bad .. When the gate is closed > good .. And the good news is that our therapeutic agent closes the gate!
In addition to broad mono-therapeutic applications, our agent can be used in combination with a wide variety of existing therapeutics as well as in concert or as a small molecule replacement for immuno-therapeutic therapies.
Two corporate venture partners comments: "Great target" and "Program significantly de-risked"
Michael Kauffman, CEO Karyopharm: “We believe that eIF4E is a compelling cancer relevant target and that Translational Therapeutics has an efficient path to proof-of-concept that could lead to a completely novel therapy which should have both single agent activity and enhance other therapies with a good tolerability profile.”
Please contact us to learn more about our efforts to develop an important new system based approach to treating human cancers .. And be sure to check back often as we grow our updated website!
Thank you for your interest.
Translational Therapeutics, Inc. 163 Scituate Street Arlington, MA 02476 781.483.3266 firstname.lastname@example.org